YOLFTbeta
Belite Bio Inc ADR

Belite Bio Inc ADR

BLTE · NASDAQ · Healthcare / Biotechnology

164.36USD-5.61 (-3.30%)

Price History

Full chart

Market Stats

Previous Close169.96
Open170.75
Day Range156.43 – 170.75
52-Week Range105.88 – 200.00
Volume216.97K
Market Cap6.28B
P/E (TTM)0.00
Forward P/E384.62
EPS-2.74
Dividend Yield0.00%
Beta-1.19
50-Day Avg160.83
200-Day Avg160.11

About

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Yu-Hsin Lin M.B.A., Ph.D.
  • Employees41
  • Headquarters12750 High Bluff Drive, San Diego, CA, United States, 92130, USA
  • Websitehttps://www.belitebio.com

Leadership

  • Dr. Yu-Hsin Lin M.B.A., Ph.D.Chairman of the Board of Directors & CEO · b. 1978
  • Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A.CFO & Director · b. 1984
  • Dr. Nathan L. Mata Ph.D.Chief Scientific Officer · b. 1966
  • Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D.Chief Medical Officer · b. 1969
  • Ms. Kelly KilpatrickChief Commercial Officer

Financials

Income Statement

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue000000
Cost of Revenue17.00K30.00K198.00K399.00K449.00K-
Gross Profit-17.00K-30.00K-198.00K-399.00K-449.00K-
Operating Expense5.73M9.77M12.62M31.27M39.55M-
Operating Income-5.74M-9.80M-12.82M-31.67M-40.00M-84.21M
EBITDA-5.73M-9.64M-12.43M-31.20M-35.67M-77.15M
Net Income-5.75M-9.67M-12.65M-31.63M-36.14M-77.61M
R&D3.69M7.42M8.87M24.84M29.94M45.38M
Interest Expense21.00K5.00K16.00K25.00K20.00K2.00K

Balance Sheet

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets25.74M18.35M44.27M94.64M152.13M780.56M
Total Liabilities32.78M33.44M2.77M4.21M6.31M10.07M
Total Equity-7.04M-15.09M41.50M90.43M145.82M770.49M
Cash25.62M17.34M42.09M88.16M31.68M352.93M
Total Debt31.81M31.81M866.00K886.00K537.00K429.00K
Net Debt6.19M14.46M-41.22M-87.27M-31.14M-352.50M

Cash Flow

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-4.44M-7.47M-11.46M-29.84M-29.23M-36.99M
Investing Cash Flow-20.00K-56.00K-394.00K-63.00K-110.57M-305.11M
Financing Cash Flow28.06M-583.00K36.96M75.96M83.59M663.23M
Capital Expenditure20.00K74.00K394.00K63.00K151.00K178.00K
Free Cash Flow-4.46M-7.55M-11.85M-29.90M-29.39M-37.17M
FCF to OCF100.45%100.99%103.44%100.21%100.52%100.48%

Earnings

Report DateJan 21, 2022Apr 29, 2022Aug 10, 2022Nov 3, 2022Mar 31, 2023May 10, 2023Aug 9, 2023Nov 14, 2023Mar 11, 2024May 14, 2024Aug 9, 2024Nov 12, 2024Mar 17, 2025May 14, 2025Aug 11, 2025Nov 10, 2025Mar 2, 2026May 20, 2026Aug 12, 2026Nov 9, 2026Nov 12, 2026
EPS Estimate--0.28-0.28-0.24-0.17-0.23-0.30-0.32-0.30-0.28-0.26-0.30-0.32-0.36-0.42-0.49-0.54-0.64-0.73-0.73-0.73
EPS Actual-0.20-0.40-0.07-0.24-0.37-0.33-0.26-0.40-0.25-0.27-0.31-0.28-0.32-0.45-0.50-0.65-0.70-0.68-0.70--
Surprise--42.86%75.00%0.00%-117.65%-43.48%13.33%-25.00%16.67%3.57%-19.23%6.67%0.00%-25.00%-19.05%-32.65%-29.63%-6.25%4.11%--
Timing-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-market-Pre-marketPre-marketPre-marketPre-marketPre-market-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap6.28B
Enterprise Value5.81B
Trailing P/E0.00
Forward P/E384.62
Price / Sales0.00
Price / Book8.12
EPS-2.74
Book Value19.29
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-118.49M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-22.10%
Return on Assets-15.65%
Shares Outstanding40.27M
Shares Float19.53M
Beta-1.19
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 9 analystsTarget 227.44
  • Strong Buy
    7
  • Buy
    2

Ownership Breakdown

Institutions
24.34%
Insiders
43.70%
Retail / Other
31.96%

Top Institutional Holders

  • Darwin Global Management, Ltd.
    3.08M7.64%
  • Paradigm Biocapital Advisors LP
    1.23M3.06%
  • RTW INVESTMENTS, LLC
    715.33K1.78%
  • Millennium Management LLC
    494.56K1.23%
  • Maverick Capital Ltd
    396.31K0.98%
  • Eventide Asset Management, LLC
    390.83K0.97%
  • Deerfield Management Co
    357.20K0.89%
  • Holocene Advisors, LP
    251.03K0.62%
  • Logos Global Management LP
    250.00K0.62%
  • Morgan Stanley - Brokerage Accounts
    235.07K0.58%
  • UBS Group AG
    224.99K0.56%
  • Citadel Advisors Llc
    186.17K0.46%
  • The Goldman Sachs Group Inc
    166.19K0.41%
  • Affinity Asset Advisors, LLC
    165.00K0.41%
  • MPM Oncology Impact Management LP
    137.21K0.34%
  • Bank of America Corp
    124.78K0.31%
  • Patient Square Capital LP
    110.00K0.27%
  • Duquesne Family Office LLC
    106.10K0.26%

Top Fund Holders

  • Eventide Healthcare & Life Sciences I
    390.83K0.97%
  • T. Rowe Price Health Sciences
    157.76K0.39%